Get the Stockscreener App
1.69
0.60%
0.01
Processa Pharmaceuticals Inc stock is traded at $1.69, with a volume of 22,052.
It is up +0.60% in the last 24 hours and down -8.65% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
See More
Previous Close:
$1.68
Open:
$1.69
24h Volume:
22,052
Relative Volume:
0.06
Market Cap:
$4.72M
Revenue:
Net Income/Loss:
$-14.11M
P/E Ratio:
-0.1577
EPS:
-10.7181
Net Cash Flow:
$-13.60M
1W Performance:
+11.18%
1M Performance:
-8.65%
6M Performance:
-46.86%
1Y Performance:
-81.23%
1-Day Range:
$1.61
$1.75
1-Week Range:
$1.50
$1.98
52-Week Range:
$1.041
$10.84
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
1.69 | 4.72M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Form PRE 14A Processa Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com Canada
Processa Pharmaceuticals files prospectus for 306.574M share sale - scanx.trade
Processa Pharmaceuticals Proposes Reverse Stock Split Following Merger with Vidya Therapeutics - Kalkine Media
Selling stockholders would receive resale proceeds, with none going to Processa (Nasdaq: PCSA). - Stock Titan
Processa Pharmaceuticals Files Amended 8-K/A Including Financials for Vidya Therapeutics Acquisition - Kalkine Media
Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208 By Investing.com - Investing.com Canada
Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208 By Investing.com - Investing.com UK
Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push - Investing.com Canada
Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push - Investing.com UK
Processa Pharmaceuticals Inc. (PCSA) Peer Comparison – Compare with Others - Value Research
Processa Pharmaceuticals Inc. (PCSA) Key Financial Ratios – Valuation, Profitability & More - Value Research
Processa Pharmaceuticals Inc. (PCSA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
A doctor on Processa Pharmaceuticals' board will present at two investor conferences on Sept. 10 and 11. - Stock Titan
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Processa Pharmaceuticals Inc. (PCSA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Processa (PCSA) Range: Closes 0.47% Lower at $2.14 in Latest Trading; Next Test: Support at $2.03 and Resistance at $2.25 Frame the RangeDark Pool Volume - vinanet.vn
Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control - Stock Titan
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsChaikin Flow - dars.gov.et
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsLinear Regression - vinanet.vn
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsDay Trade Opportunities - dars.gov.et
Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary - TradingView
Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition - Stock Titan
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com Nigeria
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com UK
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com India
Processa Pharmaceuticals (PCSA) Slips 2.34% to $2.5 as Support at $2.38 Comes into FocusPercent Above MA - vinanet.vn
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com UK
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Canada
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Processa Pharmaceuticals (PCSA) Surges 11.74% to $2.57 — Poised for a Test of $2.70 ResistanceQuality Factor - vinanet.vn
Processa Pharmaceuticals Inc (PCSA) Stock News Today - TradingKey
Processa Pharmaceuticals Inc (PCSA) Earnings, Actual EPS, EPS Estimates & Results - stocktwits.com
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Share Price, PCSA Stock News, PCSA Share Price & Updates - Kalkine
Processa Pharmaceuticals, Inc. 8-K SEC Filing Details – Nasdaq Listed Company Information (July 30, 2026) - Minichart
Processa Pharmaceuticals Shareholders Approve Key Governance Changes - TipRanks
Processa Pharmaceuticals (NASDAQ: PCSA) adds 200,000 incentive shares - Stock Titan
Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction - Mintz
Form 4 Processa Pharmaceuticals Inc For: 30 July By Investing.com - Investing.com Nigeria
Processa acquires Vidya and its BTK inhibitor - The Pharma Letter
Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors - marketscreener.com
Processa Merges With Vidya and Secures $200 Million PIPE; Terminates Elion License - TradingView
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA - GlobeNewswire
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jul 01 '26 |
Buy |
1.93 |
3,057 |
5,900 |
15,492 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 30 '26 |
Buy |
1.93 |
2,106 |
4,065 |
13,113 |
| Young David | Pres. Research & Development |
Jun 30 '26 |
Buy |
1.93 |
2,531 |
4,885 |
21,729 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 30 '26 |
Buy |
1.93 |
3,277 |
6,325 |
16,689 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 15 '26 |
Buy |
2.22 |
1,831 |
4,065 |
11,007 |
| Young David | Pres. Research & Development |
Jun 15 '26 |
Buy |
2.22 |
2,067 |
4,589 |
19,198 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 15 '26 |
Buy |
2.22 |
2,654 |
5,892 |
13,412 |
| Ng George K | Chief Executive Officer |
Jun 15 '26 |
Buy |
2.22 |
2,465 |
5,472 |
12,435 |
| Guy Wendy | Chief Administrative Officer |
Jun 15 '26 |
Buy |
2.22 |
2,118 |
4,702 |
11,958 |
| SKIBSTED RUSSELL | Chief Financial Officer |
May 29 '26 |
Buy |
2.57 |
2,292 |
5,890 |
10,758 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):